Published in Rev Urol on January 01, 2001
Cancer statistics, 2001. CA Cancer J Clin (2001) 11.73
Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol (2000) 8.08
Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst (2001) 2.82
Biomarker risk assessment and bladder cancer detection in a cohort exposed to benzidine. J Natl Cancer Inst (2001) 2.41
Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study. Urol Oncol (2011) 1.00
Long-term mitomycin C instillation after transurethral resection of superficial bladder carcinoma: influence on recurrence, progression and survival. J Urol (1984) 0.95
The changing natural history of renal cell carcinoma. J Urol (2001) 4.72
Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol (2001) 4.22
RNA polymerase II C-terminal repeat influences response to transcriptional enhancer signals. Nature (1990) 2.46
Rat macrophage lysosomal membrane antigen recognized by monoclonal antibody ED1. Immunology (1994) 2.32
Polymorphism in RANTES chemokine promoter affects HIV-1 disease progression. Proc Natl Acad Sci U S A (1999) 2.17
Glucose toxicity and the development of diabetes in mice with muscle-specific inactivation of GLUT4. J Clin Invest (2001) 2.01
Prospective evaluation of endorectal magnetic resonance imaging to detect tumor foci in men with prior negative prostastic biopsy: a pilot study. J Urol (1999) 1.63
A model to explore the interaction between muscle insulin resistance and beta-cell dysfunction in the development of type 2 diabetes. Diabetes (2000) 1.55
Cryosurgical ablation for prostate cancer: preliminary results of a new advanced technique. Isr Med Assoc J (2001) 1.42
Obstructive uropathy secondary to ureteroinguinal herniation. Rev Urol (2001) 1.33
Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma. N Engl J Med (2001) 1.29
Cutting edge: rapid cloning of tumor-specific CTL suitable for adoptive immunotherapy of melanoma. J Immunol (1999) 1.28
Elevated prostate specific antigen serum levels after intravesical instillation of bacillus Calmette-Guerin. J Urol (2000) 1.27
Metformin does not affect risk of biochemical recurrence following radical prostatectomy: results from the SEARCH database. Prostate Cancer Prostatic Dis (2013) 1.20
A shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response. J Immunol (2000) 1.18
Diabetic ketoacidosis and hyperglycemic hyperosmolar nonketotic syndrome. Endocrinol Metab Clin North Am (2000) 1.17
Paraneoplastic "stiff person syndrome" with metastatic adenocarcinoma and anti-Ri antibodies. Neurology (2004) 1.15
Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J Clin Oncol (1999) 1.15
Incidental renal tumors. Urology (2000) 1.11
A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma. Br J Cancer (2011) 1.10
Race is associated with discontinuation of active surveillance of low-risk prostate cancer: results from the Duke Prostate Center. Prostate Cancer Prostatic Dis (2012) 1.10
Mechanism of catabolite repression of tryptophanase synthesis in Escherichia coli. Microbiology (1994) 1.08
Gene and immune-based therapies for genitourinary malignancies: current status and future prospects. Isr Med Assoc J (2000) 1.07
Race and prostate weight as independent predictors for biochemical recurrence after radical prostatectomy. Prostate Cancer Prostatic Dis (2008) 1.07
Prostate cryoablation using direct transperineal placement of ultrathin probes through a 17-gauge brachytherapy template-technique and preliminary results. Urology (2001) 1.05
Identification of a positive regulatory element responsible for tissue-specific expression of prostate-specific antigen. Cancer Res (1997) 1.04
Prostate biopsies from black men express higher levels of aggressive disease biomarkers than prostate biopsies from white men. Prostate Cancer Prostatic Dis (2011) 1.03
Comparative in vitro activity of ABT-773, a novel antibacterial ketolide. Antimicrob Agents Chemother (2001) 1.02
Effect of intermittent fasting on prostate cancer tumor growth in a mouse model. Prostate Cancer Prostatic Dis (2010) 1.01
Female urethral adenocarcinoma: immunohistochemical evidence of more than 1 tissue of origin. J Urol (1999) 1.00
The influence of hepatic function on prostate cancer outcomes after radical prostatectomy. Prostate Cancer Prostatic Dis (2010) 1.00
Lifestyle interventions influence relative errors in self-reported diet intake of sodium and potassium. Ann Epidemiol (2001) 0.98
Diabetes and prostate cancer risk in the REDUCE trial. Prostate Cancer Prostatic Dis (2011) 0.97
The effects of DNA containing CpG motif on dendritic cells. Immunology (2000) 0.96
Prostate tissue specificity of the prostate-specific antigen promoter isolated from a patient with prostate cancer. Hum Gene Ther (1995) 0.95
The effect of race on the discriminatory accuracy of models to predict biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases. Prostate Cancer Prostatic Dis (2009) 0.95
Third-generation cryosurgery for primary and recurrent prostate cancer. BJU Int (2004) 0.94
CL1-GFP: an androgen independent metastatic tumor model for prostate cancer. J Urol (2000) 0.93
Predictive value of digital rectal examination for prostate cancer detection is modified by obesity. Prostate Cancer Prostatic Dis (2011) 0.93
Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor. Cancer Res (2001) 0.92
Preoperative weight change and risk of adverse outcome following radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital database. Prostate Cancer Prostatic Dis (2011) 0.92
Patient morbidity and management patterns of community-based primary health care services in Hong Kong. Hong Kong Med J (2011) 0.90
Spinal cord proliferative sparganosis in Taiwan: a case report. Neurosurgery (1987) 0.90
Validation of the ucla integrated staging system for patients with renal cell carcinoma. J Clin Oncol (2001) 0.89
In vivo trafficking of adoptively transferred interleukin-2 expanded tumor-infiltrating lymphocytes and peripheral blood lymphocytes. Results of a double gene marking trial. J Clin Invest (1996) 0.89
Biology of renal cell carcinoma: changing concepts in classification and staging. Semin Urol Oncol (2001) 0.89
Actinomycin D and gemcitabine synergistically sensitize androgen-independent prostate cancer cells to Apo2L/TRAIL-mediated apoptosis. J Immunother (2001) 0.87
Impact of nerve sparing on surgical margins and biochemical recurrence: results from the SEARCH database. Prostate Cancer Prostatic Dis (2008) 0.87
Health related quality of life outcomes in patients treated for metastatic kidney cancer: a pilot study. J Urol (1997) 0.87
Prostate cancer risk in men with prostate and breast cancer family history: results from the REDUCE study (R1). J Intern Med (2012) 0.87
The health-related quality of life and survival of small-cell lung cancer patients: results of a companion study to CALGB 9033. Qual Life Res (2002) 0.87
Anhydrolide macrolides. 1. Synthesis and antibacterial activity of 2,3-anhydro-6-O-methyl 11,12-carbamate erythromycin A analogues. J Med Chem (1998) 0.86
In vitro modulation of tumor progression-associated properties of hormone refractory prostate carcinoma cell lines by cytokines. Cancer (1996) 0.85
Interleukin 2 gene therapy for prostate cancer: phase I clinical trial and basic biology. Hum Gene Ther (2001) 0.85
Prognostic factors and molecular markers for renal cell carcinoma. Expert Rev Anticancer Ther (2001) 0.84
Reevaluation of the 1997 TNM classification for renal cell carcinoma: T1 and T2 cutoff point at 4.5 rather than 7 cm. better correlates with clinical outcome. J Urol (2001) 0.84
Survey of symptoms following intake of pyridostigmine during the Persian Gulf war. Isr J Med Sci (1992) 0.84
Exercise therapy across the prostate cancer continuum. Prostate Cancer Prostatic Dis (2009) 0.84
Adenocarcinoma of the urachus and bladder expresses a unique colonic epithelial epitope: an immunohistochemical study. J Urol (1997) 0.83
Polyarteritis nodosa presenting as hematuria and a testicular mass. J Urol (2001) 0.83
Chemotherapy of head louse (Pediculus humanus capitis) infestation gamma benzene hexachloride (gamma-BHC) among school children in Szu-Hu District, Yunlin County, Central West Taiwan. Zhonghua Yi Xue Za Zhi (Taipei) (1991) 0.83
The uncertain relationship between obesity and prostate cancer: an Italian biopsy cohort analysis. Eur J Surg Oncol (2011) 0.83
Bladder cancer 2000: molecular markers for the diagnosis of transitional cell carcinoma. Rev Urol (2001) 0.82
Monoclonal antibodies to metacyclic stage antigens of Trypanosoma cruzi. Am J Trop Med Hyg (1985) 0.82
Color and duplex Doppler sonography of hemangiopericytoma. J Clin Ultrasound (2001) 0.82
Behçet's syndrome with left ventricular aneurysm and ruptured renal artery pseudoaneurysm. Urology (1999) 0.82
Fish oil slows prostate cancer xenograft growth relative to other dietary fats and is associated with decreased mitochondrial and insulin pathway gene expression. Prostate Cancer Prostatic Dis (2013) 0.82
Preoperative predictors of blood loss at the time of radical prostatectomy: results from the SEARCH database. Prostate Cancer Prostatic Dis (2009) 0.82
Management of penile toilet seat injury--report of two cases. Can J Urol (2001) 0.81
Modulation of tumor-infiltrating lymphocytes derived from human renal cell carcinoma by interleukin-4. J Immunother (1991) (1992) 0.80
Endovascular stent graft for management of ureteroarterial fistula after orthotopic bladder substitution. Tech Urol (1999) 0.80
Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies. Br J Cancer (2011) 0.80
Can we lower the mortality rate of black men with prostate cancer? J Urol (2000) 0.80
Decreased glutathione in patients with anorexia nervosa. Risk factor for toxic liver injury? Eur J Clin Nutr (2004) 0.80
Comparative studies on epimastigote and metacyclic stages of Trypanosoma cruzi. II. Selective lysis by rodent sera. Int J Zoonoses (1985) 0.79
Acquired immunity in rats against Angiostrongylus cantonensis infection. Int J Parasitol (1989) 0.79
Immunotherapy of prostate cancer. Curr Urol Rep (2001) 0.79
The place of VEGF inhibition in the current management of renal cell carcinoma. Br J Cancer (2006) 0.79
Simultaneous use of two retroviral vectors in human gene marking trials: feasibility and potential applications. Hum Gene Ther (1992) 0.79
Improvements in the infectivity of cryopreserved third-stage larvae of Angiostrongylus cantonensis using a programmable freezer. Parasitol Res (1999) 0.78